TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00973765
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2 pills po BID x 7 days
Study: NCT01457521
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen
Study: NCT01190878
Drug: ISV-303
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% of bromfenac in DuraSite dosed QD
Study: NCT01190878
Drug: ISV-303
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% of bromfenac in DuraSite dosed BID
Study: NCT01190878
Drug: Xibrom™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% bromfenac dosed BID
Study: NCT00233103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03731988
Drug: MAL application
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study: NCT03349515
Drug: Group B will receive three drops in each eye of ophthalmic balanced salt solution.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
Study: NCT02943759
Drug: Neem leaf extract
Normalized name: neem leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial
Study: NCT02872467
Drug: Syntocinon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
Study: NCT01085591
Drug: CB-183,315
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01085591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05818618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral gel applied locally on OLP lesions.
Study: NCT02201238
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium
Study: NCT02401295
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00653965
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04360044
Drug: THC ~5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 puffs of vaporized flower containing THC \~5%
Study: NCT00005047
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005047
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01335581
Drug: Retin-A and microdermabrasion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdermabrasion and topical lightening agent regimen
Study: NCT00242489
Drug: MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04360044
Drug: CBD ~12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 puffs of vaporized flower containing CBD \~12%
Study: NCT04360044
Drug: THC ~5% and CBD ~12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 puffs of vaporized flower containing THC \~5% and CBD \~12%
Study: NCT00072020
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00667810
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Study: NCT00242489
Drug: Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00361335
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
Study: NCT00361335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
Study: NCT03241342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
Study: NCT03445650
Drug: ADX-102 1% Topical Dermal Cream (reproxalap)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
Study: NCT03445650
Drug: Vehicle of ADX-102 Topical Dermal Cream
Normalized name: Dermal-Soothe Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
Study: NCT00512993
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
Study: NCT03309007
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
Study: NCT03318276
Drug: Rinexin® Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinexin® Tab is administrated to patients with PAD for 12 weeks
Study: NCT01295294
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg 3 times daily per oral during bleeding/spotting episodes
Study: NCT01295294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times daily per oral during bleeding/spotting episodes
Study: NCT03261960
Drug: BLI4700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bowel preparation
Study: NCT02963376
Drug: 0.10 mL/kg DDFPe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
Study: NCT01695746
Drug: C.E.R.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
Study: NCT02963376
Drug: 0.10 mL/kg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
Study: NCT00755859
Drug: steroids plus azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
Study: NCT00755859
Drug: steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
Study: NCT03979781
Drug: tailored antiplatelet selection
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
Study: NCT03709823
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg cellulose powder to match final weight of the cytisine tablet
Study: NCT02960919
Drug: oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02960919
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03939884
Drug: Voltaren Topical
Normalized name: Voltaren Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Study: NCT02963376
Drug: 0.17 mL/kg DDFPe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
Study: NCT04163978
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in situ 240mL nitric oxide releasing sinus irrigation solution
Study: NCT03939884
Drug: Nivea, Topical Cream
Normalized name: Nivea, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Study: NCT01797601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin dilution medium without insulin
Study: NCT01537029
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed by the patient's treating physician according to local standard of care.
Study: NCT01537029
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dosage form: IV, Dosage, frequency, and duration: According to local standard of care
Study: NCT01964703
Drug: Rubus occidentalis extract
Normalized name: Rubus ursinus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02467010
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
Study: NCT00115687
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00757757
Drug: MCS110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-M-CSF antibody
Study: NCT04492020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Study: NCT03858192
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for infection and reason for admission
Study: NCT00048204
Drug: GW597599B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04790838
Drug: Test
Normalized name: Testro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT04790838
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT02075671
Drug: Aminolevulinic acid topical solution 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention used in the experimental arm only
Study: NCT02517437
Drug: Suprascapular & axillary blocks
Approvals — FDA: no, EMA: no, PMDA: no
Description: After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
Study: NCT02693093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02963376
Drug: 0.17 mL/kg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
Study: NCT01291017
Drug: PD0332991
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD0332991 125 mg PO days 1 - 21
Study: NCT01330771
Drug: hMG-HP/r-FSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03785366
Drug: VeraCept
Approvals — FDA: no, EMA: no, PMDA: no
Description: VeraCept Intrauterine Device (IUD)
Study: NCT04809935
Drug: 98% dehydrated alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: * coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol.
Study: NCT04258475
Drug: Calcium carbonate antacid tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
Study: NCT00649818
Drug: Ativan Tablets 2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg, single dose fasting
Study: NCT04580121
Drug: RO7283420
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
Study: NCT04580121
Drug: RO7283420
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
Study: NCT04580121
Drug: Paracetamol/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
Study: NCT01775865
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 weeks of daily salsalate
Study: NCT01775865
Drug: Placebo (for salsalate)
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 week of daily placebo
Study: NCT01708590
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneous (SC)
Study: NCT00760565
Drug: RO4905417
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg iv every 28 days for 3 infusions
Study: NCT00760565
Drug: RO4905417
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg iv every 28 days for 3 infusions
Study: NCT00760565
Drug: RO4905417
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7mg/kg iv every 28 days for 3 infusions
Study: NCT00760565
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg iv every 28 days for 3 infusions
Study: NCT00760565
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7mg/kg iv every 28 days for 3 infusions
Study: NCT00760565
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg iv every 28 days for 3 infusions
Study: NCT01805830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
Study: NCT00752830
Drug: AZD0328
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, single dose
Study: NCT01802749
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01394952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01884428
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
Study: NCT01335997
Drug: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
Study: NCT01335997
Drug: Simvastatin (SIM)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 10 mg oral tablet taken once daily
Study: NCT01335997
Drug: Placebo Run-In
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
Study: NCT01335997
Drug: SIM-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for simvastatin 10 mg oral tablet taken once daily
Study: NCT02289235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder 2 capsules twice daily for 3 months
Study: NCT00560430
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo; orally weeks 1-14
Study: NCT00362921
Drug: Gliadel wafers in combination with O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00838708
Drug: SRD174 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical SRD174 Cream
Study: NCT03054259
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250ml infusion on days 1 and 15
Study: NCT02219971
Drug: Kukoamine B Mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Study: NCT03668314
Drug: RDN-929
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose from 2 mg to TBD
Study: NCT03668314
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo Single dose
Study: NCT01150890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.
Study: NCT01804218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03668314
Drug: RDN-929
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose based on results of previous cohorts
Study: NCT03668314
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo multiple dose
Study: NCT00186043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02497313
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01046266
Drug: RO5083945
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700mg iv weekly
Study: NCT01362127
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
Study: NCT03015727
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
Study: NCT00001576
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00473460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules orally once daily for 5 days every 8 weeks.
Study: NCT01516307
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
Study: NCT02182791
Drug: EE/NET
Normalized name: EE/NETHDRONE (EQV-FEMHRT 1/5) TAB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03709459
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be asked to take Doxycycline 100mg/day for 12months duration
Study: NCT00923000
Drug: Nubian with Long dan xie gan tang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration